Nevisense for Melanoma
Detection of Malignant Melanoma
CommercialApproved (CE Mark, FDA De Novo)
Key Facts
Indication
Detection of Malignant Melanoma
Phase
Commercial
Status
Approved (CE Mark, FDA De Novo)
Company
About Scibase
SciBase's mission is to pioneer prediction and prevention in skin health by empowering clinicians with advanced diagnostic tools. Its key achievement is the development and commercialization of the Nevisense platform, which has gained regulatory approval for melanoma and keratinocyte cancer detection based on robust clinical evidence. The company's strategy focuses on expanding the platform's applications, scaling commercial operations in key markets, and leveraging its unique EIS+AI technology to become a standard of care in dermatological diagnostics.
View full company profile